Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →ML Fraud Detection Score: 87%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
39,584
Total Claims
$4.2M
Drug Cost
1,809
Beneficiaries
$2,318
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+334%
Opioid rate vs peers
9.7% vs 2.2% avg
+64%
Cost per patient vs peers
$2,318 vs $1,411 avg
+8%
Brand preference vs peers
11.4% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
ML fraud detection score of 87% indicates prescribing patterns with significant similarity to confirmed fraud cases. 17 out of 20 decision trees flagged this provider.
Opioid rate is 334% above Internal Medicine peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
9.7%
Opioid Rate
3,846
Opioid Claims
$110K
Opioid Cost
2.8%
Long-Acting Rate
Brand vs Generic
Brand: 4,492 claims · $3.3M
Generic: 34,814 claims · $872K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 406 | $331K |
| Semaglutide | 206 | $281K |
| Vismodegib | 11 | $166K |
| Rivaroxaban | 160 | $149K |
| Empagliflozin | 112 | $147K |
| Fluticasone/Umeclidin/Vilanter | 133 | $145K |
| Interferon Beta-1a/Albumin | 12 | $129K |
| Dapagliflozin Propanediol | 94 | $116K |
| Semaglutide | 57 | $102K |
| Budesonide/Formoterol Fumarate | 161 | $101K |
| Insulin Glargine,hum.Rec.Anlog | 89 | $100K |
| Dulaglutide | 63 | $80K |
| Cariprazine Hcl | 52 | $77K |
| Sacubitril/Valsartan | 66 | $67K |
| Fluticasone Propion/Salmeterol | 121 | $61K |
Prescribing Profile
Patient Profile
72
Avg Age
58%
Female
1.93
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data